Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Milad Alucozai

Investment Partner , Angel

Overview

Gender
male
Investor Type
Investment Partner,Angel
Investor Stage
Early stage Venture,Seed

Milad strives to make a positive contribution to the world by backing purpose-driven entrepreneurs working to address real problems using breakthrough technologies.

Milad leads Life Sciences at BoxOne Ventures, a privately held investment firm that focuses on early-stage companies. He is also a Venture Partner at Entrepreneur First, a global fund with a portfolio value of over $5 billion. In 2022, he was appointed as a Strategic Advisor to LifeOmic, a precision health startup founded by serial entrepreneur Don Brown. In 2020, he was appointed as an External Advisor to AstraZeneca (NASDAQ:AZN), working on initiatives to partner more closely with startups. He continues to proudly serve as a mentor for groups like the Creative Destruction Lab and Harvard University iLabs. He has also served as an advisor to startups like Numerate, a San Francisco-based drug discovery company (acquired by Valo Health), and Absci, a Vancouver-based AI-powered synthetic biology company that recently went public.

Milad began his career as a bench scientist working in translational neuroscience and multiphysics labs and transitioned into founding roles at multiple healthcare and bio startups. He is part of the founding team at Mekonos, a San Francisco-based company building a platform for cell delivery supporting the future of cell and gene therapies. Prior to this, he served on the founding team at Corstem, a company specializing in machine learning and artificial intelligence software (acquired by Circle Cardiovascular, a platform used in over 1000 hospitals and in more than 40 countries). During his time at Accenture, Milad led data scientists, designers, and engineers focused on building AI products for global pharmaceutical companies and hospital networks.

Milad is a former Visiting Scholar in Healthcare Engineering at the Regenstrief Center. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine and graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed graduate school in Immunology & Public Health.

Personal Investments

Number of Investments
4
Milad Alucozai has made 4 investments. Their most recent investment was on Apr 28, 2022, when CytoTronics raised $9.25M.
Date Company Name Round Money Raised Industry
May 18, 2022 Isabl Inc. Seed $3M Biotechnology Detail
Apr 28, 2022 CytoTronics Seed $9.25M Test and Measurement Detail
Mar 9, 2022 Colossal Biosciences Series A $60M Biotechnology Detail
May 12, 2021 Juno Diagnostics Series A $25M Biotechnology Detail

Jobs

Number of Current Jobs
2
Milad Alucozai has 2 current jobs including External Advisor at AstraZeneca , Mentor at Creative Destruction Lab (CDL) and .
Organization Name Title At Company Start Date End Date
AstraZeneca External Advisor Sep 1, 2020 Detail
Creative Destruction Lab (CDL) Mentor Jan 1, 2019 Detail